Managing Kratom Withdrawal with Clonidine and Buprenorphine
Kratom Use Disorder Management Using Clonidine and/or Buprenorphine
This study is testing if Clonidine and Buprenorphine can help adults going through Kratom withdrawal feel better by using different treatment combinations over 12 weeks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 20 Years to 99 Years |
| Sex | All |
| Sponsor | Salem Anaesthesia Pain Clinic Academic / other |
| Locations | 1 site (Surrey, British Columbia) |
| Trial ID | NCT05883358 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on adults experiencing Kratom withdrawal, exploring the effectiveness of Clonidine and Buprenorphine in managing withdrawal symptoms. Participants will receive alternating treatments of either Buprenorphine patches, Clonidine tablets, or a combination of both over a 12-week period. Data on withdrawal severity will be collected daily using the Subjective Opiate Withdrawal Scale (SOWS) and weekly using the Clinical Opiate Withdrawal Scale (COWS). The study aims to improve understanding and management of Kratom withdrawal, which is currently under-researched.
Who should consider this trial
Good fit: Ideal candidates are adults who are dependent on Kratom and experiencing withdrawal symptoms.
Not a fit: Patients with cognitive disorders or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide effective management strategies for individuals suffering from Kratom withdrawal, improving their recovery outcomes.
How similar studies have performed: While there is limited research specifically on Kratom withdrawal, studies on opioid withdrawal management using similar medications have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients * Kratom dependence * Kratom withdrawal syndrome * Kratom withdrawal therapy * good treatment compliance * reliable Subjective Opiate Withdrawal Scale (SOWS) diary * reliable Clinical Opiate Withdrawal Scale (COWS) diary * informed consent for diary review * consent for clinical record quality assurance review Exclusion Criteria: * poor treatment compliance * cognitive disorder * inability to provide consent * major neuropsychiatric disorder * unreliable diary * cannabis use * excessive alcohol intake * previous adverse/allergic reactions to clonidine * previous adverse/allergic reactions to buprenorphine
Where this trial is running
Surrey, British Columbia
- Salem Anaesthesia Pain Clinic — Surrey, British Columbia, Canada (Recruiting)
Study contacts
- Principal investigator: Olu Bamgbade, MD,FRCPC — Salem Anaesthesia Pain Clinic
- Study coordinator: Olu Bamgbade, MD,FRCPC
- Email: salem.painclinic@gmail.com
- Phone: 17786286600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.